| chronic pain (diagnosis)

Belbuca vs Nucynta ER

Side-by-side clinical, coverage, and cost comparison for chronic pain (diagnosis).

Deep comparison between: Belbuca vs Nucynta with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsNucynta has a higher rate of injection site reactions vs Belbuca based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Nucynta but not Belbuca, including UnitedHealthcare

Category

Belbuca

Nucynta

At A Glance

RouteBuccal film

FrequencyEvery 12 hours

ClassPartial opioid agonist

RouteOral

FrequencyTwice daily

ClassOpioid agonist / NRI

Indications

chronic pain (diagnosis)

chronic pain (diagnosis)
Diabetic peripheral neuropathy

Dosing

chronic pain (diagnosis) 75 mcg buccal film once daily or every 12 hours for opioid-naive patients, titrated in increments of 150 mcg every 12 hours no more frequently than every 4 days to a maximum of 900 mcg every 12 hours; initial dose for opioid-experienced patients: 150 mcg every 12 hours (30-89 mg oral MSE) or 300 mcg every 12 hours (90-160 mg oral MSE).

chronic pain (diagnosis), Diabetic peripheral neuropathy Initiate at 50 mg orally every 12 hours in opioid-naive patients; titrate by 50 mg increments no more than twice daily every three days; maximum total daily dose 500 mg.

Moderate hepatic impairment Initiate at 50 mg no more than once every 24 hours; maximum 100 mg per day; regularly evaluate for respiratory and CNS depression.

Contraindications

Significant respiratory depression
Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
Known or suspected gastrointestinal obstruction, including paralytic ileus
Hypersensitivity (e.g., anaphylaxis) to buprenorphine

Significant respiratory depression
Acute or severe bronchial asthma or hypercarbia in an unmonitored setting or in the absence of resuscitative equipment
Known or suspected gastrointestinal obstruction, including paralytic ileus
Hypersensitivity to tapentadol or any other ingredient of the product
Concurrent use of MAOIs or use within the last 14 days

Drug Interactions

890View drug interactions

409View drug interactions

Adverse Reactions

Most common (>=5%) Nausea, constipation, headache, vomiting, fatigue, dizziness, somnolence

Serious Addiction, abuse, and misuse; life-threatening respiratory depression; interactions with benzodiazepines and CNS depressants; neonatal opioid withdrawal syndrome; QTc prolongation; hepatotoxicity; anaphylactic/allergic reactions; seizures

Postmarketing Serotonin syndrome, adrenal insufficiency, anaphylaxis, androgen deficiency, hyperalgesia and allodynia, dental decay (caries, tooth fracture, and tooth loss), hypoglycemia, opioid-induced esophageal dysfunction

Most common (>=10%) Nausea, constipation, dizziness, headache, somnolence, vomiting

Serious Respiratory depression, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, neonatal opioid withdrawal syndrome

Postmarketing Hallucination, suicidal ideation, panic attack, anaphylaxis, androgen deficiency, hyperalgesia, allodynia, hypoglycemia, opioid-induced esophageal dysfunction

Pharmacology

Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor; it produces analgesia by binding with high affinity to opioid receptors on neurons in the brain and spinal cord and, unlike full opioid agonists, exhibits a dose-ceiling effect on respiratory depression.

Tapentadol is a centrally-acting synthetic analgesic that acts as a mu-opioid receptor (MOR) agonist and norepinephrine reuptake inhibitor (NRI); analgesia in animal models is derived from both properties, though the exact mechanism in humans is unknown.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Belbuca